To objective of this study is to investigate the incidence of adverse events (AEs) and adverse drug reactions (ADRs) occurred following administration of Efluelda® in adults aged 65 years or older under routine clinical practice, as per approved indications This is an open-label, multi-center, observational active safety surveillance study, designed to be conducted under standard healthcare setting of the Republic of Korea, in accordance with "Regulation on the Operation of Risk Management Plans". The study duration of each participation will be approximately 28 to 35 days. In the event that Visit 2 is not made, the study duration would be extended to 36 to 42 days.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Occurrence of solicited injected site reactions.
Timeframe: Up to 7 days after vaccination
Occurrence of solicited systemic reactions
Timeframe: Up to 7 days after vaccination
Occurrence of unsolicited Adverse Events (AE)
Timeframe: From vaccination to Visit 2 (up to approximately 42 days)
Occurrence of unsolicited Adverse Drug Reactions (ADR)
Timeframe: From vaccination to Visit 2 (up to approximately 42 days)
Occurrence of unexpected Adverse Events (AE)
Timeframe: From vaccination to participant's last contact (up to approximately 42 days)
Occurrence of unexpected Adverse Drug Reactions (ADR)
Timeframe: From vaccination to participant's last contact (up to approximately 42 days)
Occurrence of Serious Adverse Events (SAE)
Timeframe: From vaccination to participant's last contact (up to approximately 42 days)
Trial Transparency email recommended (Toll free for US & Canada)
Occurrence of unexpected Serious Adverse Drug Reactions (SADR)
Timeframe: From vaccination to participant's last contact (up to approximately 42 days)
Occurrence of Adverse Event of Special Interest (AESI)
Timeframe: From vaccination to participant's last contact (up to approximately 42 days)